TG-C

TG-C offers a regeneration technology that assists in the treatment of damaged tendons, ligaments, cartilages, and bones. It involves minimally invasive injections versus a surgical approach. TG-C is based on the infection of primary chondrocytes with a retroviral vector expressing transforming growth factor-beta1 (TGF-beta1), followed by the intra-articular injection of the modified cells. The vector is a MoMSV/MoMLV hybrid-based retroviral vector, which is devoid of gag, pol or env gene sequences, such that replication competent retrovirus is not generated by recombination with homologous sequences in a viral packaging system. The vector contains a CMV major immediate early gene promoter/enhancer driving expression of the TGF-beta1 gene.